Menveo Group A (meningococcal Group A C W135 and Y conjugate vaccine): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

Menveo Group A,C,W135 and Y conjugate vaccine

Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

The use of this vaccine should be in accordance with official recommendations.


Molecule: meningococcal Group A, C, W135 and Y conjugate vaccine

Patients' opinions on Menveo Group A

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.